{"slideshow_credits": null, "snippet": "The announcement, an apparent first for a major drug company, would end a common practice that is criticized for posing a conflict of interest.", "abstract": "British drug maker GlaxoSmithKline will no longer pay doctors to promote its products and will stop tying compensation of sales representatives to number of prescriptions doctors write; move effectively ends two common industry practices that critics have long assailed as troublesome conflicts of interest; announcement appears to be a first for a major drug company, although others may be considering similar moves.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}], "original": "By KATIE THOMAS"}, "web_url": "http://www.nytimes.com/2013/12/17/business/glaxo-says-it-will-stop-paying-doctors-to-promote-drugs.html", "lead_paragraph": "The announcement, an apparent first for a major drug company, would end a common practice that is criticized for posing a conflict of interest.", "headline": {"main": "Glaxo Says It Will Stop Paying Doctors to Promote Drugs", "print_headline": "Glaxo to Stop Paying Doctors to Boost Drugs"}, "_id": "52af941238f0d804c251c832", "word_count": "1183", "multimedia": [{"height": 126, "url": "images/2013/12/17/business/17glaxo/17glaxo-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2013/12/17/business/17glaxo/17glaxo-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 388, "url": "images/2013/12/17/business/17glaxo/17glaxo-articleLarge.jpg", "legacy": {"xlarge": "images/2013/12/17/business/17glaxo/17glaxo-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "388"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2013/12/17/business/17glaxo/17glaxo-thumbStandard.jpg", "legacy": {"thumbnail": "images/2013/12/17/business/17glaxo/17glaxo-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2013-12-17T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Conflicts of Interest", "name": "subject", "is_major": "Y", "rank": "5"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "GlaxoSmithKline PLC", "name": "organizations", "is_major": "Y", "rank": "1"}, {"value": "Doctors", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Ethics (Institutional)", "name": "subject", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}